The complex process by which dozens of protein products will shift from regulation as drugs to biologics in March 2020 may face renewed scrutiny at an upcoming US Food and Drug Administration hearing on biosimilar and interchangeable insulins.
Under the Biologics Price Competition and Innovation Act “transition provisions,” insulin, human growth hormone and certain other types of protein products historically regulated as drugs under the Food, Drug and Cosmetic Act